We could see him now.

He's Brian Pinker.

Um, he describes himself as Oxford born and bred on.

He said she read you the statement.

It's rather lovely, he says.

I'm so pleased to be getting the cove in vaccine today.

Really proud that it's one was invented in Oxford.

The nurses, doctors and staff today have all been brilliant.

I can really look forward to celebrating my 40th wedding anniversary with my wife, Shirley, later this year.

Happy anniversary.

Sam Foster was the chief nurse there who was administering the vaccine this morning.

We've spoken to her already on BBC Breakfast's morning.

She was talking to our medical editor, Fergus Walsh.

She was back outside the hospital in Oxford this morning.

Incredibly busy.

Ferguson a really big step forward this morning.

It is a huge step forward because this vaccine, not just for the UK but globally, will have a major impact.

It is far cheaper than the fighter job far easier to transport and store.

It can be transported and kept in a fridge, unlike the fires, a jab which has to be moved up minor.

70.

So it's gonna have a big impact.

It could go in tow, every care home easily within the next few weeks.

It could go to anywhere in the world because AstraZeneca has said it will produce three billion doses at cost this year on its promised, also never to make a profit from low on middle income countries.

Well, I'm delighted to say that the global head of clinical trials off the Oxford AstraZeneca vaccine press, Andrew Polities with me press apology.

I think you've just received your dose, too.

I have just received my dose as a health care worker here in Oxford on I'm really delighted to have been able to do so.

It's an absolute triumph for all of the team have been working on the vaccine this year.

We are just a few 100 m from where the first trials have done in April, a few 100 m from where the team the lister designed this I mean extraordinary that ah university, albeit a prestigious one, should produce ah vaccine in the space of a year that could have on incredibly impact on bringing this pandemic under control.

It's an amazing academic collaboration that brings us not just here in Oxford, but the trial sites around the UK and internationally, with academic groups driving forward this program Thio to meet this point today where we see the first doses rolled out.

So when you saw Brian Pinker getting getting his job that the vaccine approved what was running through your mind then I was so pleased to see someone here in Oxford who's been brought up in Oxford so excited to receive the first days of the vaccine, which was developed here.

I know it's just being limited to a few centers on Day one.

Why is that?

But it's been limited to a few centers just to get started and work out all the logistics.

But I'm hoping that the NHS will be set up for a major role out over the weeks ahead.

In terms of the sort of level of protection it gives.

People are getting one dose on, then they're getting their second dose 12 weeks later.

Now, do you have any idea what level of protection has been all sorts of numbers flying around what level of protection it will give people well in the clinical trials once the immune response kicks in and that takes a few weeks after you've been vaccinated, we've seen up until the second date around about 70% protection.

There is also potentially protection against severe disease, which is really more important.

Wealthy information from the trials really shows that the vaccine is protecting people against severe infection and hospitalization.

In fact, after immune responses kicked in, we didn't see anyone who ended up in hospital from that point onwards on the 70% is really against mild disease that where we're seeing that protection.

So I think this is extremely good news now, in terms off people coming forward, there are something like 30 million people in the priority groups over fifties a frontline healthcare workers like yourself, Andi, then people with underlying health conditions.

How soon do you think people that group will be protected?

Well, there's a huge logistical challenge, but I think the NHS is very much up for it on.

There's lots of work going on on supply that AstraZeneca's responsible for So I'm optimistic that we're going to get there in the months ahead on in terms of long term protection because people will eventually get their second does on you.

I think found from your trials that a bigger gap actually may actually have given better overall protection.

We certainly saw better immune responses with a longer gap at the moment, the numbers of it's more to be absolutely sure that translates into better protection.

But we think it should.

On DSO.

I think there's no harm in having a longer gap in there may be a benefit us Well, you're also a doctor here.

You've seen what's going on in hospitals pretty serious at the moment.

I think this is a is a really critical moment way are at the point of being overwhelmed by this disease, So I think it gives us a bit of hope.

But I think we've got some tough weeks ahead.

Okay, Professor Paula, thank you very much indeed.

So, as Professor Pollard said, three NHs really under pressure.

So the rollout of this vaccine really can't come soon enough, but it is a bright moment, a bright spot in what otherwise is some very grim news about what is happening to the NHS.

The intense pressure it is under from the new variant off coronavirus.